Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 2Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Plasma Cell 1Endometrial Neoplasms 1Classic Follicular Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 10Magnetic Resonance Spectroscopy 9Carboplatin 9Taxes 7Paclitaxel 7Biopsy 7temsirolimus 6Trastuzumab 5Sirolimus 5pembrolizumab 4Radiotherapy 4olaparib 3Nivolumab 3Interleukin-12 Subunit p35 3Bevacizumab 3pertuzumab 2palbociclib 2ipatasertib 2binimetinib 2aldesleukin 2X-Rays 2Thalidomide 2Reverse Transcriptase Polymerase Chain Reaction 2Oxaliplatin 2Megestrol Acetate 2Interleukin-12 2Immunoglobulin G 2Fluorouracil 2Docetaxel 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Endometrial Neoplasms × Hyaluronoglucosaminidase × Clear all
NCT05256225 2026-06-03

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡